论文部分内容阅读
目的:探讨心肌性能指数(myocardial performance index,MPI,又称Tei指数)在评价柔红霉素(daunorubicin,DNR)对急性淋巴细胞白血病(ALL)患儿心功能早期损害方面的临床应用价值。方法:测定并比较22例急性淋巴细胞白血病患儿DNR化疗前和化疗后6个月、12个月常规超声心动图参数及Tei指数,同时以25例正常健康体检儿童为对照组。结果:急性淋巴细胞白血病患儿化疗后6个月左心室Tei指数明显高于化疗前组及对照组(P<0.01),化疗前组与对照组左心室Tei指数差异无显著性(P>0.05),ALL患儿化疗后6个月左室射血分数(LVEF)、E/A比值与化疗前比较,差异均无显著性(P>0.05)。结论:Tei指数能更早、更敏感地评价DNR对急性淋巴细胞白血病患儿心脏功能损害。
Objective: To investigate the clinical value of myocardial performance index (MPI), which is also called Tei index, in evaluating early damage of cardiac function in children with acute lymphoblastic leukemia (ALL) with daunorubicin (DNR). Methods: The echocardiographic parameters and Tei index of 22 children with acute lymphoblastic leukemia before DNR and 6 months and 12 months after chemotherapy were determined and compared. At the same time, 25 normal healthy children were used as the control group. Results: The Tei index of left ventricle of children with acute lymphoblastic leukemia was significantly higher than that before chemotherapy and control group (P <0.01), and the Tei index of left ventricular before and after chemotherapy was not significantly different (P> 0.05 ). There was no significant difference in LVEF and E / A ratio between 6 months after chemotherapy in ALL patients and before chemotherapy (P> 0.05). Conclusion: The Tei index can evaluate earlier and more sensitive DNR impairment of cardiac function in children with acute lymphoblastic leukemia.